Intersect ENT (XENT) and DexCom (DXCM) Head to Head Analysis

Intersect ENT (NASDAQ: XENT) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Risk and Volatility

Intersect ENT has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

Earnings and Valuation

This table compares Intersect ENT and DexCom’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intersect ENT $96.30 million 12.22 -$16.36 million ($0.57) -69.25
DexCom $718.50 million 8.21 -$50.20 million ($0.59) -114.86

Intersect ENT has higher earnings, but lower revenue than DexCom. DexCom is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.5% of Intersect ENT shares are held by institutional investors. 13.7% of Intersect ENT shares are held by insiders. Comparatively, 1.7% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Intersect ENT and DexCom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -16.99% -14.40% -12.71%
DexCom -6.99% -13.99% -6.67%

Analyst Ratings

This is a breakdown of current ratings for Intersect ENT and DexCom, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 2 8 0 2.80
DexCom 1 6 13 0 2.60

Intersect ENT presently has a consensus price target of $33.43, suggesting a potential downside of 15.31%. DexCom has a consensus price target of $65.97, suggesting a potential downside of 2.66%. Given DexCom’s higher possible upside, analysts plainly believe DexCom is more favorable than Intersect ENT.


Intersect ENT beats DexCom on 8 of the 14 factors compared between the two stocks.

About Intersect ENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

About DexCom

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with's FREE daily email newsletter.

Leave a Reply